This trial is evaluating whether focal salvage HDR prostate brachytherapy will improve 1 primary outcome and 4 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Acute period (<6 months).
This trial requires 60 total participants across 1 different treatment group
This trial involves a single treatment. Focal Salvage HDR Prostate Brachytherapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"In patients who have undergone radical prostatectomy for high-risk prostate cancer, there was a significant but progressive decrease in clinical and PSA progression for up to 8 years according to our results. However, progression was not statistically significant after adjustment for PSA, grade, and stage at time of diagnosis and the treatment received. As most patients who received salvage radiotherapy were progression-free at 6 years, longer postprostatectomy survival might be expected. We propose that patients presenting with high-risk disease should be counselled with radical treatment modalities as the opportunity may be presented at the time of surgery." - Anonymous Online Contributor
"Men with prostate cancer may have increased urinary frequency as a result of bladder outlet obstruction. There may also be signs of the disease in the blood, including erythropoietin or hematological abnormalities. The common occurrence of erythrocytosis and anemia in the prostate cancer population may be a result of blood flow alterations." - Anonymous Online Contributor
"This is a health article of interest. It discusses all of the information to be looked for. These are some of the common questions a person may have and some of the questions they should ask about [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). There is lots of health information on prostate cancer, including information about how best to ask questions about the disease and information on prevention, screening, detection, and treatment options when prostate-related disease is suspected. The American Cancer Society and the National Comprehensive Cancer Network both provide great information about prostate cancer and treatment options. It is a disease that typically affects older men but is not uncommon to be diagnosed at a younger age." - Anonymous Online Contributor
"The most common [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in the population is multifocal or multicentric; nearly 25% of men will be diagnosed with this disease. Multifocal disease is commonly found on repeat biopsy, suggesting that focal disease might be missed when repeat biopsy is conducted. Prostate cancer is one of the more frequent benign findings on repeat core biopsy, and in patients with multifocal disease most cores demonstrate cancer." - Anonymous Online Contributor
"Many patients with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) suffer from benign prostatic hyperplasia (BPH), a condition in which the prostate does not function properly and causes problems such as painful urination during ejaculation, and incontinence. Treatment options include surgery, radiation therapy, chemotherapeutic/targeted therapy, behavioral therapy, and hormonal therapy." - Anonymous Online Contributor
"Several factors including diet, hormone replacement, radiation exposure, and lifestyle play a role in prostate cancer. Although prostate cancer happens in men of all ages and races, prostate cancer happens in men over the age of 50 and particularly in African American men." - Anonymous Online Contributor
"It is the first and only study of its type in Europe, and the only study investigating the use of hd-BRT, in addition to ISR. There was no evidence of a benefit of Hd-BRT in the ISR setting, and no difference in PSA values, in the Hd-BRT group and control group. We found a trend towards significance in respect of PSA values, but the results failed to reach the threshold for a statistical significance in this study: P (t)=0.055. It is the first report to our knowledge about this form of salvage therapy, and will be used as a basis for a larger study." - Anonymous Online Contributor
"Prostate cancer was diagnosed earlier in all age groups in 2018 compared to the previous two decades. Although incidence rates of prostate cancer increased with age, prevalence rates rose sharply in a more steep proportion with age. The current findings are consistent with predictions that age-related changes in cancer pathobiology and risk factors may contribute. Further research is needed to explore the relationship of age to the time of diagnosis, the cause of early diagnoses, and whether the increase in the age of diagnosis has a real health problem." - Anonymous Online Contributor
"Compared with other salvage options, FSHPB is often used in conjunction with other treatment options, particularly in patients with a high risk of disease recurrence." - Anonymous Online Contributor
"Men with intermediate risk Gleason 6 [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) may benefit from active surveillance after adjusting for pretreatment PSA level. However, more men (33%) will eventually undergo radical prostatectomy. The PSA rate may be an indicator of the extent of disease before radical prostatectomy and of the likelihood of cancer recurrence." - Anonymous Online Contributor
"Data from a recent study confirms that the risk of focal salvage brachytherapy is extremely low, and more so than in other studies in which no comparison to postirradiation prostatic atrophy was made. As well, the results are not comparable to those reported in other studies, owing to the study design and the use of different staging schemes. We therefore feel that patients who have previously undergone prostatectomy for local control of their disease might be the ideal candidates for local salvage brachytherapy." - Anonymous Online Contributor